Bristol Myers, Takeda to pool data for AI-based drug discovery
PositiveFinancial Markets

Bristol Myers and Takeda are joining forces to enhance drug discovery through artificial intelligence. This collaboration aims to leverage their combined data to accelerate the development of new treatments, which could significantly impact patient care and innovation in the healthcare sector. By pooling their resources, these pharmaceutical giants are setting a precedent for how AI can transform the drug development landscape, potentially leading to faster and more effective therapies.
— Curated by the World Pulse Now AI Editorial System